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Objecties. The purpose of this sludy was tocompare the e&cts 
of zatebwlime on heati Me, cantrxlility and relaxation with 
those ofits sttuctural analog verapamil. We used isoproterenol, a 
potent beIa.agonist, ta see how these effects were m&da&d by 
sympaLb& activatbn. We also compared the eff-xts of z&bra- 
dine and verapamit on coronary blond Row and coronary bled 
now reserve. 
Backgmd. Zatebmdine, previousty r&xl UL-FS 49, is 8 
new bradycardic agent believed to act selrrtively at the sb~oakial 
twde. 
Me/hods. Isolated isovdumetric pig hearts ae~ prepared and 
left veahifalar pressure, its firs4 derivative (dpldt), hu and beart 
rate were measured both kefore and after administration of either 
a.975 Ilag oflatebradiie Kkaup I, n = 8) or 12s pg of verapamil 
(Group II, II = 8). AlIetthea&ctsofeacb drug reacbheda plateau, 
a contbmuus infusion of isopmterenol was started and tneuwe- 
men& were obtakd agatn and compared with a tbtrd gmup al 
measuremea(s from cwttrol hear& infused with isoproterenol 
after receiving only saline solution (n = 8). We also abased tbe 
elk& ti zatebrrdinc and veqamit on comnsry vascular lone by 
meawing llaw in the IelI ~oterior deaaliag coronary artery in 
h&cl awsthelhed open chest pigs both kforc and after the 
intraeoranary admbkhntion of these drugs (n = ll for each). .&I 
preparaticw wre ali-ially paced to negate nybndycardic et?wts 
of the drugs. 
Rest&s. In the group that received mtebradine, man (*SE) 
hurt rate decreed Cwm 143 k 8 to 99 + 4 k&/min (p < 0.01) 
Sinus tachycardia is a common physiologic response to a 
variety of situations encountered in daily life (for example, 
exertion and emotional stress) and disease states (for exam- 
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pie, anemia and hypoxemia). Mediated by the autonomic 
nervous system, sinus mchycardia involves both vagal with- 
drawal and increased adrenergic input (I,Z). Also, for a 
number of drugs (for example, theophylline, hydmlazine and 
phoaphadiestemse inhibitors), an increase in heart 13 is 
often an unwanted side effect that limits their usefulness. 
Although increased heart rate may aid homeostaais by 
increasing cardiac output, this occurs at a cost of increased 
myocardial oxygen consumption and decreased time for 
myocardial r&x&ion and diastolic ventricular filling. AC- 
cuidiqgly, drugs that b&k sinus tachycardia or reduce the 
heart 1’ale at rest (for example, beta-adrenergic blocking 
agent and some calcium channel blockers), or both. arc 
widely used for these bndycardic properties. 
As is shown in Figure I, zatebradine (previously called 
VERAPAMIL 
ZATEBRADINE 
Figure 1. Chemical struclure of verapamil and zebradine. 
UL-FS 49) is a substituted benzazepinone that is structurally 
similar to verapamil(3.4). Unlike verapamil, however, zate- 
bradine is believed to act selectively at the sinoatrial (SA) 
node, functioning only as a negative chronotropic agent 
(5,6). Its precise mechanism of action is somewhat contro- 
versial. However, many investigators believe that it inhibits 
the hyperpolarizing-activated current (Ir) in SA tissue. It 
belongs to a second generation of compounds that habe been 
termed “specific bradycardic agents” (3.4). The aims of the 
present experiments were to: I) assess the effects of zate- 
bradine on heart rate, contractility and relaxation in an 
isolated heart preparation where potentially confounding 
effects of the autoncmic nervcnts system could be avoided; 
2) determine whether heart rate, contractility and relaxation 
can be manipulated independently by using zatebradine in 
combination with an inotropic agent; 3) assess the effects of 
zatebradine on coronary vascular tone; and 4) compare and 
contrast these various effects to those of verapamil, the 
closest structural analog to zatebradinc among the clinically 
useful calcium channel blockers. 
Methods 
Preparation of isolated perfused heart. Adult pigs weigh- 
ing approximately 60 kg were anesthetized with chloroform 
(7) and ventilated after endotracheal intubatioo. The chest 
was opened through a midline sternotomy incision. T’-e 
great vessels were isolated and the animal was treated with 
heparin (10,000 U intravenously). A cannula was inserted 
into the ascending aorta through the right common carotid 
artery, and another was inserted into the tight ventricle 
through the superior vena cava. The animal’s blood was 
collected into an oxygenator until a vohnne of I.2 liters was 
obtained. The remaining vessels, including the pulmonary 
artery, were then tied off and coronarv oerfiision was started 
I . 
th&gh the ascending aorta nsing a constant perfusion pump 
(Cardiovascular Instrument Corp.). The heart and lungs 
were then removed from the chest cavity and suspended on 
scaffolding by the trachea. The pericardium was opened and 
a cannula was inserted into the left ventricular apex to drain 
thebesian venous return. 
Th? left atria1 appendage was incised and a thin latex 
balloon was inserted into the left ventricle through the mitral 
anulus. The base of the balloon was secured to a Plexiglas 
disc and tube. The tube was connected to a saline infusion 
system and the balloon was filled to an end-diastolL pressure 
of 10 mm Hg. The left ventricle was kept isovoluaetric 
throughout the experiment. 
Aortic pressure, which in this model is equivalent IO 
coronary perfusion pressure. was measured with a Statham 
P23Db pressure transducer. Left ventricular pressure wds 
measured by using a transducer-tipped catheter (Millar In- 
struments) inserted directly into the latex balloon. A ther- 
mistor probe (Yellow Springs Instrument Co.) was placed in 
the left atrium. Electrocardiographic (ECG) leads were sewn 
into the prrirsrdk,m at the right atrium and apex ofthe heart. 
An uhrasound ,9cw probe was placed in the venous line to 
measure total (minus thebesian venous) coronary blood 
flow. 
All data were recorded on an eight-channel polygraph 
recorder (Interface 4600, Gould). The heart was maintained 
at 37°C and the blood was gassod with 95% oxygen and S% 
carbon dioxide and adjusted to keep the pH, partial pressure 
of oxygen(Po3and partid pressure of carbon dioxide (PcoJ 
in a near physiologic range. 
Preparation of Ihe intact heart. Coronary flow was as- 
sessed using intact open chest pigs. After thoracotomy and 
heparin infusion, the right carotid artery was isolated, as was 
a short segment of the proximal left anterior descending 
coronary artery. A large bore (IOF conneciion tubing with 
tapering ends) cannula was inserted into the carotid artery 
and advanced to the ascending aorta. Preliminary experi- 
ments revealed reactive hyperemia to be unchanged after 
cannula placement. After a IO-mg bolus injection of lid+ 
Caine. the distal end of the carotid cannula was inserted into 
a proximal segment of the left anterior descending coronary 
artery, effectively providing a carotid IO left anterior de 
scending coronary artery bypass circuit. The left anterior 
descending coronary artery was tied off proximal lo the 
cannlr’a insertion. intepsed between the two ends of the 
cannula was a stainless steel tube containing an ultrasound 
Doppler flow probe (Titronics Medical Instruments). The 
ECG leads were sewn to the pericardium and pacing wires 
were placed in the left alrium. A transducer-tipped catheter 
was then placed into the left ventricular chamber through a 
purse-string suture at the apex. Anesthesia was matntained 
with periodic infusions of intravenous chloroform and ven- 
tilation using 95% oxygen and 5% carbon dioxide was 
adjusted to keep pH, Pco,, ant’ PO, in a near physiologic 
range. 
Isolated heart measurements. To evaluate left ventricular 
systolic and diastolic function, the left ventricular balloon 
was inflated with saline solution until a diastolic pressure of 
10 mm Hg was achieved. This produced on average a IefI 
ventricular systolic pressure of IO0 mm Hg. The preparation 
T&lo 1. Comparative Effects of Zatebradme and Verapamd on Hcan Rate. Conlrac!iiiry and 
Relaxation in Isolated Pig Hearts 
was given 10 mitt to equilibrate; exe ‘.v~ taken to CIISU-E 
that temperature and pH were in the physiologic range and 
that there was no draft in either systolic or diastolic left 
ventricular pressure. After equilibration. the KG. coronary 
perfusion pressure, left ventricular pressure. dP/dt and cor- 
onary Bow were meascred cominuously in the control smte. 
The time constant of left ve.~tticulat relnxatmn. mu. was 
measured by the technique reported by Weiss et al. (8). 
Periodic measurements of atterial blood gases and hema- 
tocrit were also obtained. 
In the first group (n = 8). bolus injections of zatebndine 
were given until 925% reduction in heart rate was achieved 
(0.975 2 0.025 mg). Fifte*n minutes was required for re. 
equilibration after administration of the drug. The previously 
mentioned variables were once again recorded in a continu- 
ous fashion. lsoproterenol was then given by a continuous 
infusion pump (Harvard Apparatus) in a graded manner to 
achieve a dose-response curve. A second group (n = 8) wa; 
given a b&s injection of 125 clg of verapamil before the 
isonroterenol infusion and a third arouo (a = 81 received the 
iso&oterenol infusion alone. Ver&ttt~l was given in a dose 
(125 ~g) that in pilot studies prxhtced a maximal decrease in 
heart rate without killing the preparation as a result of 
depressed left ventricular function. 
ltttac~ heart tneasurements. In studies to assess coronary 
blood flow and its reserve in open cheat pigs with the 
circulation and autonomic netvons system intact, hearts 
were paced to approximately 120 beats/mitt. This was done 
in an aftemp: to negate the direct brltdycardic effect of 
zatebradine on myocardial oxygen consumption. Left ven- 
tricular pressure, the ECG, mean aortic pressure, left aatc- 
rior descending coronary artery flow and dP/dt were re- 
corded in d continuous manner as for the isolated 
experiments. After an equilibrium period, reactive hyper- 
emia was assessed with a 15-s occlusion of the left anterior 
descending artery cannula. Measurements were also ob- 
tamed after a bolus irljection byeither 50 a ofverapamil or 
I mg of zatebradine was given directly into the left anterior 
descending artery. At the concbsion of each experiment, the 
Doppler flow probe was calibrated against a known rate of 
blood flow and methyleae blue was injected into the left 
anterior descending artery to stain the tissue supplied by the 
cannulated vessel. Th: stained tissue was dissected and 
wished and thus coronary blood Row could be evaluated in 
Ierms cf milliliters per minute per gram of wet tlssae. 
Statistical analysis. All data are expressed as mean 
valoe 2 SE. Comparison among the different groups was 
made by Cog a one-way analysis of variance for repeated 
measureu. Standard multiplr co-mpanrons were performed 
with a Student-Newman-Keuls test. Although tis.e xs a 
faclor technically, we did not consider it so, as mcdsurc- 
mews were performed after a new steady state was teached 
after each manipulation. 
Rest&s 
The effects of zatebtadine and verapami! in the isolated 
heart preparation are summarized in Table I. Zatebradine 
resuhed in a 303b decrease in heart rate. There was a 
tendency toward a decrease in peak left ventricular pressure 
and dP/dt amI a shortening of mu; however, these changes 
were not statistically significant. In contrast, verapatnil led 
to a lesser decrease in heart rate (-1.2%). but produced 
major decreases in peak left ventricular pressure and dpldt 
and prolongation of tau. It is possible that a greater decrease 
in heart rate could have been achieved with a higher dose of 
verapamil; however. more of this drug was not administered 
because of myncardial depression. Figure 2 demonstrates 
the effect of isoproterenol on heart rate in preparations 
pretreated with r&bra&x. verapamil or saline sololion. 
There was a major increase in heart rate in both the 
verapami!. and saline solution-treated hearts that appears to 
plateau; however, isoproterenol failed to increase heart rate 
in the preparations first treated with zatebtadine. Figure 3 
shows that peak left ventricular pressure in these isovolu- 
metric heMa was increased by isoproterenol whether the 
hearts were treated first with saline solution. zatebradine or 
verapamil. Because of myocardial depression. peak left 
ventricular pressure started at a lower level in the verapamil- 
treated hearts. Similarly, Figure 4 demonstrates that isopro- 
terenol increased contractility as measured by dPldt whether 
hearts were pretreated with zatebmdinc, vetapamil or saline 
solution (control). However. in beans pretreated with Vera 
pamil. dPidt was substantially depressed compared with 
control hearts except at the highest two levels of isoproter- 
enol ininsion. Figure 5 shows representative tracings of left 
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Figure 2. Effect of isoproterenol on heart raie in isolated isovolu- 
m%c pig hearts pret&ted wifh verapamil (squares). zatebradine 
(circle) or saline solution (CONTROL, triangles). Values represent 
mews value * SE. *p < 0.05 compared with the value before 
isoproterenol infusion. 
ventricular p essure and dP/dt in response to isoproterenol 
in a heart pretreated with zaatebradine. 
Left ventricuIar diastolic relaxation as reflected by tau 
??‘a~. prolonged by verapamil but slighhtly shortened by zate- 
bradine. lsoproterenol markedly impmved relaxation in 
Figure 3. Effect of isoproterenol on peak left ventricular systolic 
pressure (LVP) in isolated iwvolumetic pig hearts pretreated with 
wapamil (square), zatebradine (clrclef) or saline solution (trim- 
etesh Values reuresent mean value ? SE. *D < 0.05 cornoared with 
ihe value bcfork the isoprowenol infusion: 
200 
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Figure 4. The effect of isoproterenol on the firs1 derivative of left 
ventricular prerrure (dP/dt) in isolated isovolumetric pig hearts 
pretreated with vempamil (squares), zatebradine (circia) or saline 
solution (CONTROL, triangles). Values represent mean value + 
SE. “p C 0.05 compared with the value before isoproteraol 
infusion. 
hearts pretreated with either verapamil or zatebradine (Fig. 
6). but the final relaxation rate was significantly faster (that 
is, tau was smaller) than in control hearts only in the hearts 
pretreated with zatebradine. 
In the intact open chest animals, the decrease in heart 
rate seen after the imracoronary administration of zatebra- 
dine was prevented by atrial pacing. As seen in Table 2, 
there was a tendency (p = NS) toward a reduction in peak 
left ventricular pressure and dP/dt after zatebmdine. Sod 
flow and coronary vascular resistance in the IeR anterior 
descending coronary artery were not al&ted signiiicantly 
by the administration of zatebradine iTable 2). Also. reactive 
hyperemia remained intact, with coronary blood flow in- 
creasing by about ICM after a 15-s occlusion of the vessel. 
In contrast, the administration of a small dose of verapamil 
into the teft anterior descending artery, although not at&t- 
ing peak left ventricular pressure or dP/dt, did significantly 
increase coronary blood flow. The diierence between coro- 
nary dew after verapamil and peak coronary flow as as- 
sessed by reactive hyperemia was negligible and these 
values were significantly greater than control values (Table 
2). 
Discussion 
The major finding of this study is that zatebradine selec- 
tively decreases heart rate without atTecting contractility or 
myocardial relaxation. Its bradycardir effect is not over- 
come by the potent beta-agonist isoproterenol, even though 
major improvements in contractility and relaxation are 
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achieved, as evidenced by a nearly 100% increase in left 
ventricular pressure and dP/dt and a 27% reduction in tau. 
Furthermore, unlike the nonsubstituted benzazepinone ver- 
apanil, zatebradine has virtually no vasodilatinp effects on 
the coronary arteries. The specific bradycardic effects of 
zatebradine are quantitatively and qualitatively similar to 
effects found previously by other investigators (3-6.9-I I). 
This agent has been shown to improve regional myocardial 
function during &hernia, without jeopardizing the function 
of normal myocardium, both at resl and during exercise 
(10,12,13). In previous studies (IO) in intact animals, zate- 
bradine has been shown 10 decrease heart rate, peak leit 
Figure 6. Lefl ventricular relaxalion as measured by iau at baseline. 
aRer drug !rea!men! With saline solution [trinn$Psl, verapamil 
[squares] or zalebmdine Wc+esll and after treatment with drug plus 
5 &min of isoproterenol. ‘p < 0.05 compared with Ihe baseline 
value. 
ventricular prrzsurr and dP/d!. The negative inotropic ef- 
fects were arrributed to a negative “staircase” or treppe 
effect, as !he dPidt normalized toward control heart ra!es 
etch atnal pacieg (IO). This would be similar to the negative 
staircase effect demonsrrated with verapanil in isolated 
perfused rabbit hearts (14). Early investigations (4.15) with 
this substance revealed that in both intact conscious animals 
and isolated tissue. zatebradine could affect both heart rate 
and contrx!i;ity, depending on the dose used. However, 
dose-response curves showed that the specitkity for heart 
rate was tnree orders of magnitude hitier than that for 
contrdctili!y (4.15). The negative chronotropic effect is also 
dependent on the baseline heart rate-a greater percent 
change being seen where the starting hear! rate is highest. 
Our studies demonstrate the effects of zatebradine on the 
isolated, isovolumetric blood-perfused pig hear!. Although 
we found a significant decrease in heart rate and only a smdl 
trend toward negative inotropy. it should be emphasized that 
the preparations received a fairly large uniform dose of 
zatebradine. Furthermore our intent was to give a dasa that 
JAW ‘,‘“i. *1, NO. 2 
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would decrease the heart rate by approximately 30%, irre- 
spective ofthe absolute initial value. It is possible that higher 
doses of zatebradine would have produced significant dec- 
rements in peak left ventricular pressure and dPidt. Al- 
though our results are qualitatively similar to those of 
Johnston et al. (5), the latter investigators assessed right 
ventricular prcssurc and contractility during conditions un- 
der which loading conditions were not kept constant; in 
contrast, we investigated the e.fects of zatebradine and 
verapamil in the isovolumetric left ventricle with ConstEnt 
preload. Furthermore, in a study by Schipke et al. (3), 
although isolated canine hearts were used, the issue of 
neurohormonal influence was not entirely resolved because 
intact support animals were used. Finally, our study di%s 
from others in that we assessed left ventricular diastolic 
relaxation by measuring tau in the isovolumetric isolated left 
ventricle. 
The precise mecha&m of action of zatebradine is uncer- 
tain. An action through inhibition of a calcium currenl was 
first presumed to be the case because of the structural 
similarity of zatebradine to verapamil (Fig. I). Voltage (clamp 
experiments (IS-19 with isolated SA node cells have qihown 
that zatebradine inhibits the slow inward calcium c;lrrent. 
Radioligand binding studies have shown diffuse mytrardial 
binding sites. Voltage clamp studies (l3,lg) have also dem- 
onstrated an apparently different mechanism of action com- 
pared with verapamil from the standpoint of sodium, potas- 
sium and calcium currents; zatebradine blocks the calcium 
channel current in SA node cells at drug concentrations with 
little or no effect on other cell types. More recently (6), it has 
been proposed that zatebradine may work by inhibiting the 
hyperpolarizing-activated current (Ir) at the SA node. Previ- 
ous experiments (19.20) in conscious animals demonstrated 
no effect with isoproterenol after pretreatment with zatebra- 
dine. Our studies in the is&led heart revealed profound 
ir.creases in contractility with isoproterenol after pretreat- 
ment with zatebradine. These disparate results could be due 
to the peripheral vasodilating beta, effectsof isoproterenol in 
the intact animal. 
It has been suggested that zatebradine may be beneficial 
in patients with coronary artery disease. Regional myocar- 
dial blood flow and regional conlractility have both heen 
shown to improve after administration of zatebradine in 
intact animals with experimentally induced ischemia (IO). 
Furthermore, in contrast to beta-blockers, the drug does not 
affect nonischemic regions. Also, the theoretic unmasking of 
epicardia1 coronary vasoconstriction by beta-blockade 
would be avoided. 
Anuther structural congener of verapamil, AQ-A 39, is 
also a relatively specific bradycardic agenr (3.18,21); when 
tried in humans with ischemic heart disease and depressed 
left ventricular function, it was shown to improve symptoms 
without further depressing left ventncular function 02.23). 
However, AQ-A j9 has been shown to be less potent’ani 
less specific than zatebradine in terms of its bradycardic 
effect (15). The negative chronotropic effect of zatebradine 
was not overcome by isoproterc ,101 in our studies, a finding 
similar to that shown previously with AQ-A 39 (18,211. 
Because coronary autoregulation is compromised in the 
isolated heart preparation, we looked at the effect of zate- 
bradine on coronary vaacilidr tone in intact ape:! chest 
animals: virtually no vasodil&on was seen. 
By slowing the intrinsic heart rate, myocardial oxygen 
consumption is presumably decreased without sacrificing 
inotropy. More time is spent in diastole, allowing for in- 
creased ventricular filling and myocardial perfusion. By 
decreasing the oxygen demandisupply ratio, zatehradine 
could potentially become a useful agent ag&st myocardial 
ischemia: it is particularly enticing that this new class of 
specific bradycardic agents may become useful for the 
management of ischemia in the setting of depressed leti 
ventricular function. If pretreatment with zatebsadine in the 
clinical setting prevents the tachycardia associated with the 
administration of Ma-agonists, it is possible that this drug 
could become useful in treating patients with acute conges- 
tive hear! failure by preventing the rachycardia associated 
with potent inotropic agents. 
Zatebradine may also be useful in the treatment of 
chronic congestive heart failure, especially if there is a major 
component of diastolic dysfunction. Cardiac muscle from 
patients with advanced cardiomyopathy undergoing heart 
transplantation has been shown to exhibit slowing of dia- 
stolic relaxation associated with impaired calcium removal 
from the cytosol (24,25). This impaired calcium cyclieg is 
worsened with increasing heart rate (241, such that cardio- 
myopathic muscle shows anegative treppe or staircase effeci 
(that is. the strength of contraction is inveraety proportiona; 
to rate), the opposite of the situation seen in normal human 
heart muscle (26). Thus, prevention uf tachycardia may be 
expected to have both positive inotropic and lusitropic 
elEcts in chronic congestive heart failure (27). Furthermore, 
chronic tachycardia itself has been shown to produce dilated 
cardiomyopathy in normal hearts (283EJ and it is intriguing 
to speculate that a substantial reduction in heart rate in 
patients with existing cardiomyopathy might prevent pro- 
gression ofthis disease. It is clear thatfurtherinvestigations, 
both basic and clinical, need to be performed with specific 
bradycardic drugs such as zatebradine. 
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